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methodAbstract Antipyrine and benzocaine are formulated together for the treatment of ear inﬂamma-
tion and to relieve pain. Four spectrophotometric methods were developed for the simultaneous
determination of antipyrine (AN) and benzocaine (BE) in their combined dosage form. Method
A depends on applying dual wavelength method where antipyrine was determined by measuring
the absorbance at 254.1 and 309.1 nm (corresponding to zero difference of benzocaine), while the
absorbance difference at 230.1 and 263.5 nm (corresponding to zero difference of antipyrine) was
selected for benzocaine determination in the laboratory prepared spectrum. Method B depends
on measuring the peak amplitude of ﬁrst derivative at 305 nm for calculating benzocaine concentra-
tion then the total concentration of both drugs was determined using isoabsorptive point at
257.4 nm (antipyrine concentration was then calculated by subtraction). Method C is based on mea-
suring the peak difference of the ratio spectra at Dp (239.1–285 nm) and Dp (301.4–250 nm) for the
determination of antipyrine and benzocaine, respectively. Method D depends on measuring peak to
peak amplitude of the ﬁrst derivative of ratio spectra at (234.5 + 244.2 nm) and peak amplitude at
295.5 nm for the determination of antipyrine and benzocaine, respectively. The proposed methods
were validated and applied for the analysis of antipyrine and benzocaine in their laboratory pre-
pared mixtures and pharmaceutical formulation. Statistical comparison between the results of
the proposed methods and those of the reported methods showed no signiﬁcant difference.
 2016 Publishing services provided by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Antipyrine (phenazone) (AN, Fig. 1) is 1, 5-Dimethyl-2-phe
nyl-4-pyrazolin-3-one, it is a NSAID that can relieve mild to
moderate pain.1 It is an ofﬁcial drug in USP2 and BP3 pharma-
copeia. Several analytical methods were reported for the deter-
mination of AN either alone or coformulated with other drugs
including spectrophotometric,4,5 chemometric,6,7 HPLC,8,9
Benzocaine, C9H11NO2, 
M.Wt 165.19
Antipyrine, C11H11N2O, 
M.Wt 188.23
Figure 1 The chemical structures of benzocaine and antipyrine.
182 H.A. MereyTLC,10,11 GC,12,13, capillary zone electrophoresis14 and non
aqueous titration15 methods. Benzocaine (BE, Fig. 1) is a ben-
zoic acid, 4-amino, ethyl ester (ethyl 4-aminobenzoate) acid
ester. It is used as a local anesthetics for superﬁcial anesthesia,
for the local and temporal relief of pain related, to buccal
infections.1 BE is ofﬁcial in USP2 and BP3 pharmacopeia.
BE was determined by several methods including; spectropho-
tometry16–21, and HPLC.22–26 HPLC method was also
reported as a stability indicating method for BE.27 Antipyrine
(AN) and benzocaine (BE) are co-formulated in Egyptian mar-
ket as ear drops for relief of pain and reduction of inﬂamma-
tion in the ear as in otitis externa and acute otitis media15.
Usually combined dosage forms require more sophisticated
analytical methods especially when their components interfere
with each other during their analysis and control procedures to
resolve the interference.28 Only two HPLC methods were elab-
orated for the determination of benzocaine and antipyrine in
the presence of BE degradation product.29,30 One TLC method
was reported for the determination of benzocaine and antipyr-
ine in the presence of BE degradation product.30 From litera-
ture in hand, no spectrophotometric methods were used for the
simultaneous determination of AN and BE, therefore the aim
of this work was to develop and validate simple, precise, rapid
and accurate spectrophotometric methods for the simultane-
ous determination of AN and BE in pure form or in pharma-
ceutical formulation.
2. Experimental
2.1. Instruments
SHIMADZU dual beam UV–visible spectrophotometer
(Kyoto/Japan), model UV-1650 PC with a ﬁxed slit width
(1 nm). The bundle software is UV-Probe version 2.21 (Shi-
madzu). The instrument is equipped with HP1020 laser jet
printer.
2.2. Chemicals and solvents
All chemicals used were of analytical grade: Double distilled
water (SEDICO Pharmaceutical Co., Cairo, Egypt). Ethanol
(Lab. Scan, Ireland).
2.3. Samples
2.3.1. Pure samples
 Antipyrine (phenazone) and Benzocaine were kindly sup-
plied by Amriya for pharmaceutical industries, Alexandria,
Egypt. Purity of AN and BE was found to be 100.22
± 1.375 and 99.47 ± 1.071 according to its reported
method.30
2.3.2. Pharmaceutical formulation
 Otosept ear drops are labeled to contain 300 mg of anti-
pyrine and 100 mg of benzocaine in 10 mL of glycerin, It
is manufactured by Amriya for pharmaceutical industries,
(Alexandria, Egypt). Batch No. 8571031 was purchased
from Egyptian markets.2.4. Standard solutions
2.4.1. Stock standard solutions
 Antipyrine (1 mg mL1)
The solution was prepared by dissolving 100 mg of AN in
100 mL double distilled water.
 Benzocaine (0.4 mg mL1)
The solution was prepared by dissolving 40 mg of BE in the
least amount of ethanol then complete to 100 mL using
double distilled water.
2.4.2. Working standard solutions of AN (100 lg mL1) and
BE (40 lg mL1)
AN and BE working solutions were prepared by diluting
10 mL from their respective stock standard solutions
1 mg mL1 and 0.4 mg mL1 (for AN and BE, respectively)
into two separate 100-mL volumetric ﬂasks and the volume
was completed with double distilled water.
2.5. Laboratory prepared mixtures
Different aliquots of AN and BE were separately transferred
from their working standard solutions (100 lg mL1 and
40 lg mL1, respectively) into a set of 10-mL volumetric ﬂasks
then the volume was completed to the mark with double dis-
tilled water to produce laboratory prepared mixtures contain-
ing different ratios of the cited drugs.
3. Procedure
ICH guidelines31 for method validation were followed.
3.1. Spectral characteristics
Zero order absorption spectra of 30 lg mL1 AN and
10 lg mL1 BE in double distilled water were recorded over
a wavelength range of 200–400 nm.
3.2. Linearity
Aliquots of AN and BE were separately transferred from their
working standard solutions (100 lg mL1 and 40 lg mL1,
respectively) into two separate sets of 10-mL volumetric ﬂasks.
The volume was then made up to the mark with double dis-
tilled water to give samples having concentrations in the range
of 5–50 lg mL1 for AN and 1–20 lg mL1 for BE. The zero
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200 to 400 nm and stored.
3.2.1. For dual wavelength method (method A)
A calibration curve was constructed relating the absorbance
difference DA at 254.1 and 309.1 nm to the corresponding con-
centrations of AN. While for benzocaine the absorbance dif-
ference DA at 230.1 and 263.5 nm was plotted against the
corresponding concentrations of BE. The regression equations
and correlation coefﬁcients were computed.
3.2.2. For first derivative coupled with isoabsorpative method
(method B)
First derivative of the stored zero order absorption spectra of
BE was obtained using Dk= 8 and scaling factor = 10 and
the peak amplitude at 305 nm (zero contribution of AN) was
recorded and plotted against the corresponding BE concentra-
tions then the regression equation was computed. The absor-
bance of the stored zero order absorption spectra of AN at
257.4 nm was recorded and plotted against the corresponding
AN concentrations then the regression equation was
computed.
3.2.3. For ratio difference method (method C)
The stored spectra of AN were divided by standard spectrum
of BE (4 lg mL1) as a divisor, then the values of peak differ-
ence of the obtained the ratio spectra at Dp (239.1–285 nm)
were plotted against corresponding concentration of AN.
Similarly, the stored spectra of BE were divided by standard
spectrum of AN (5 lg mL1) as a divisor and the values of peak
difference of the obtained ratio spectra at Dp (301.4–250 nm)
were calculated and plotted against corresponding concentra-
tions of BE. The corresponding regression equations were also
computed.
3.2.4. For derivative ratio spectra spectrophotometric method
(method D)
The ﬁrst derivative of the previously obtained ratio spectra of
AN and BE (1DD) were manipulated using Dk= 4 and scal-
ing factor = 10. The values of peak to peak of the obtained
ﬁrst derivative ratio spectra at (234.5 + 244.2 nm) and the
peak amplitude at 295.5 nm were plotted against the corre-
sponding concentrations of AN and BE, respectively. The
regression equations and correlation coefﬁcients were also
computed.
3.3. Accuracy
The suggested methods have been applied for measuring dif-
ferent concentrations of AN and BE within their linearity
ranges and the concentrations were calculated each from their
corresponding regression equation. The percentage recoveries
and SD for each drug were calculated. The validity of the pro-
posed methods was further assessed by applying the standard
addition technique.
3.4. Precision
Repeatability: Three concentrations of AN (5, 30 and
50 lg mL1) and BE (4, 8 and 12 lg mL1) were analyzedthree times in triplicate on the same day, using the previously
mentioned procedure under linearity. SD values were then cal-
culated for each drug.
Intermediate precision: The above mentioned concentra-
tions of AN and BE were analyzed on three successive days
using the procedure stated under linearity. SD values for each
drug were then calculated.
3.5. Specificity
The zero order absorption spectra of laboratory prepared mix-
tures were recorded, then the procedures were applied as
described under linearity for each proposed method. The con-
centrations of AN and BE were calculated by substituting in
the corresponding regression equations.
3.6. Application of the proposed methods for the determination
of AN and BE in Otosept ear drops
A volume of ear drops equivalent to 30 mg AN and 10 mg BE
was transferred into volumetric ﬂask 100 mL then the volume
was completed to the mark with double distilled water. An
appropriate dilution was made using double distilled water
to obtain solutions of ﬁnal concentrations of AN and BE
within their linearity. Then the procedure was completed as
described under linearity. The concentrations of the cited
drugs were obtained from the computed corresponding regres-
sion equations.
4. Results and discussion
By reviewing the literature it was revealed that, only two arti-
cles have been published as stability indicating methods for
determination of benzocaine and antipyrine in the presence
of degradation product of BE29,30. No spectrophotometric
methods were reported for the simultaneous analysis of AN
and BE, this attract our attention to develop simple, rapid,
precise and validated spectrophotometric methods for the
simultaneous determination of AN and BE in pure form or
in pharmaceutical formulation. Spectrophotometric methods
do not require sample preparation, expensive instruments in
addition to being less time consuming and economical in com-
parison to the HPLC method.
Dual wavelength spectrophotometric method offers an efﬁ-
cient method for analyzing a component in the presence of an
interfering component. For elimination of interferences, dual
analytical wavelengths were selected in a way to make the
absorbance difference zero for one drug in order to analyze
the other drug.32. Fig. 2 shows sever overlap between AN
and BE in the wavelength range of 200–330 nm, so direct
determination of AN and BE cannot be applied. Therefore,
dual wave length was ﬁrst tried for determination of the cited
drugs. For the determination of AN, two wavelengths (254.1
and 309.1 nm) were selected where the absorbance difference
between these wavelengths was directly proportional to the
concentrations of AN in the concentration range of 5–
50 lg mL1, while the absorbance difference of BE at these
wavelengths was zero. The absorbance difference at 230.1
and 263.5 nm was selected for determination of BE in the con-
centration range of 1–20 lg mL1, whereas, the absorbance
difference of AN at these wavelengths was zero.
Figure 2 Zero order absorption spectra of 30 lg mL1 anti-
pyrine (. . .. . .) and 10 lg mL1 benzocaine (_____) using double
distilled water as a blank.
Figure 3 First derivative spectra of 30 lg mL1 antipyrine
(. . .. . .) and 10 lg mL1 benzocaine (_____) using double distilled
water as a blank.
Figure 4 Zero order absorption spectra of 20 lg mL1 anti-
pyrine (. . .. . .), 20 lg mL1 benzocaine (______) and laboratory
prepared mixture containing 10 lg mL1 of each (- - - - -) using
double distilled water as a blank.
184 H.A. MereyDerivative spectrophotometry is a well-established tech-
nique capable of enhancing the resolution of overlapped spec-
tra. It can be applied for the determination of a substance in
the presence of the other, by selecting wavelength where the
contribution of one compound is zero while the other to be
determined has a reasonable value.33.
It was found that, the ﬁrst derivative spectrophotometry
(1D) failed to determine AN but BE can be selectively deter-
mined by measuring the peak amplitude of the ﬁrst derivative
spectra at 305 nm (Fig. 3). Therefore, derivative spectropho-
tometry was coupled with isoabsorpative point spectrophoto-
metric method to determine the total concentrations of AN
and BE at 257.4 nm then AN concentration can be calculated
by subtraction (Fig. 4).
Recently, ratio difference spectrophotometric method was
introduced as a novel method for the simultaneous determina-
tion of mixtures with overlapped spectra, in which the ampli-
tude difference between two points on the ratio spectra of a
mixture is directly proportional to the concentration of the
component of interest; independence of the interfering compo-
nent is the basic principle of the ratio difference method.34
To apply this method for the simultaneous determination
of AN and BE, different concentrations of AN and BE were
tried as a divisor (1, 2 and 4 lg mL1, BE) and (5, 10 and
20 lg mL1, AN) for the determination of AN and BE, respec-
tively. The selected divisor should compromise between low
noise and maximum sensitivity. The best results were obtained
upon using 4 lg mL1 of BE and 5 lg mL1 of AN as a divisor
for the determination of AN and BE, respectively.
For the determination of AN concentration by the ratio dif-
ference method, after using BE as a divisor the only require-
ment was the contribution of the AN and BE at the two
selected wavelengths (239.1 and 285 nm) where the ratio spec-
tra of the BE showed the same amplitudes (constant) whereas
AN ratio spectra showed signiﬁcant difference in amplitudevalues at these two selected wavelengths with concentration,
(Fig. 5). Similarly, another two wavelengths (250 and
301.4 nm) were selected for the determination of the BE after
using AN as a divisor, (Fig. 6). The selected wavelengths were
found to be the best regarding sensitivity and linearity.
Figure 6 Ratio spectra of (1–20 lg mL1) benzocaine (_____) and
the constant of antipyrine (- - - - -) using the spectrum of
5 lg mL1 antipyrine as a divisor.
Spectrophotometric methods for determination of antipyrine and benzocaine 185Derivative ratio spectra spectrophotometric method was
one of the popular methods used to solve the overlapped spec-
tra.35 It was tested for analysis of AN and BE in binary mix-
tures. This method was based on obtaining the ratio spectra
of studied drug by dividing its absorption spectra by a stan-
dard spectrum of the interfering compound then the ﬁrst
derivative of the ratio spectra was computed. The main param-
eters that affect the sensitivity of derivative ratio spectra
method are concentration of divisor and the wavelength incre-
ment over which the derivative is determined. The best results
were obtained when using the spectrum of 4 lg mL1 BE and
5 lg mL1 AN as a divisor for the determination of AN and
BE, respectively. Satisfying results regarding signal to noise
ratio were obtained upon using Dk= 4 and scaling fac-
tor = 10 (Figs. 7 and 8). Upon using the previous conditions,
the peak to peak of the ﬁrst derivative of the ratio spectra at
(234.5 + 244.2 nm) and the peak amplitude at 295.5 nm were
used for the analysis of AN and BE, respectively.
4.1. Method validation
4.1.1. Linearity
 For dual wavelength method
Under the previous experimental conditions it was found
that, linear relationship was obtained between the absor-
bance difference at the selected wavelengths (DA 254.1–309.1
and DA 230.1–263.5) and the corresponding concentrations
of AN and BE. The regression equations were computed
and the results are listed in Table 1.
 For ﬁrst derivative coupled with isoabsorpative method
The linear correlation was obtained between the peak
amplitude of the ﬁrst derivative spectra at 305 nm and the
corresponding concentrations of BE. The regression equa-
tion was computed. The linear correlation was obtained
between the absorbance of AN at 257.4 nm and the corre-
sponding concentrations of AN. This linearity was used
to calculate the total concentration of AN and BE by
substituting the absorbance of binary mixture orFigure 5 Ratio spectra of (5–50 lg mL1) antipyrine (_____) and
the constant of benzocaine (- - - - -) using the spectrum of
4 lg mL1 benzocaine as a divisor.
Figure 7 The ﬁrst derivative of ratio spectra of (5–50 lg mL1)
antipyrine (_____) using the spectrum of 4 lg mL1 benzocaine as a
divisor.pharmaceutical formulation in equation to get the total
concentration followed by subtraction the concentration
of BE to found AN concentration. The regression equation
was computed and the results are listed in Table 1.
 For ratio difference method
A linear relationship was obtained between the amplitude
ratio difference (DP239.1–285) and (DP301.4–250) versus
the corresponding concentration in the ranges of
5–50 lg mL1 and 1–20 lg mL1 for AN and BE, respec-
tively. The parameters of the corresponding regression
equations are shown in Table 1.
 For derivative ratio spectra spectrophotometric method
A linear relationship was obtained between the peak to
peak amplitude of the ﬁrst derivative ratio spectra at
Figure 8 The ﬁrst derivative of ratio spectra of (1–20 lg mL1)
benzocaine (_____) using the spectrum of 5 lg mL1 antipyrine as a
divisor.
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186 H.A. Merey(234.5 + 244.2 nm) and the peak amplitude at 295.5 nm
versus the corresponding concentration in the ranges of
5–50 lg mL1 and 1–20 lg mL1 for AN and BE, respec-
tively. The data of the corresponding regression equations
are shown in Table 1.
4.1.2. Accuracy
The suggested methods were applied for measuring different
concentrations of AN and BE within their linearity range
and the concentrations were calculated each from their cor-
responding regression equations. The accuracy of the pro-
posed methods was further assessed by applying the
standard addition technique. Good results were obtained
(Tables 1–3). Statistical comparison between the results
obtained by the proposed spectrophotometric methods and
the reported method30 for the determination of pure antipyr-
ine and benzocaine in pure powder form was also done. The
values of calculated t and F are less than the tabulated ones,
which reveals that there is no signiﬁcant difference between
the suggested methods with respect to accuracy and preci-
sion, (Table 4).
4.1.3. Precision
Precision was evaluated by calculating intra- and interday
precision after repeating the assay of the three different
concentrations three times in the same day and assaying
the sample in triplicate on three successive days using
the proposed methods. The calculated S.D. was listed in
Table 1 indicating satisfying precision of the proposed
methods.
4.1.4. Specificity
Good recoveries were obtained upon applying the proposed
methods for the determination of studied drugs in laboratory
prepared mixtures containing different concentrations of AN
and BE indicating good speciﬁcity (Table 5).
Table 2 Analysis of Otosept* ear drops and application of the standard addition technique to the determination of benzocaine and
antipyrine in Otosept* ear drops by the proposed spectrophotometric methods (A and B).
The proposed method Otosept ear dropsa Standard addition technique
Found%± SD Pure added (lg mL1) Pure found* (lg mL1) Recovery %
Dual Wavelength method Antipyrine 5 4.93 98.60
97.08 ± 1.667 10 9.98 99.80
20 19.79 98.95
Mean ± SD 99.17 ± 0.617
Benzocaine 4 4.03 100.75
98.44 ± 0.443 8 8.06 100.75
12 11.87 98.92
Mean ± SD 100.14 ± 1.058
First derivative coupled with
isoabsorpative method
Antipyrine 5 5.04 100.80
97.36 ± 0.642 10 10.06 100.60
20 19.64 98.20
Mean ± SD 99.87 ± 1.447
Benzocaine 4 4.01 100.25
99.21 ± 1.138 8 7.87 98.39
12 12.18 101.50
Mean ± SD 100.04 ± 1.570
Method A is dual wavelength, method B is ﬁrst derivative coupled with isoabsorpative point.
* Average of three experiments.
a Batch No. 857103.1
Table 3 Analysis of Otosept* ear drops and application of the standard addition technique to the determination of benzocaine and
antipyrine in Otosept* ear drops by the proposed spectrophotometric methods (C and D).
The proposed method Otosept ear dropsa Standard addition technique
Recovery ± SD Pure added (lg mL1) Pure found* (lg mL1) Recovery %
Ratio diﬀerence method Antipyrine 5 5.03 100.60
97.67 ± 0.792 10 10.04 100.40
20 19.77 98.85
Mean ± SD 99.95 ± 0.958
Benzocaine 4 4.02 100. 50
99.78 ± 1.231 8 7.97 99.63
12 12.15 101.25
Mean ± SD 100.46 ± 0.813
Derivative ratio spectra method Antipyrine 5 4.95 99.00
98.41 ± 0.405 10 10.15 101.50
20 19.79 98. 95
Mean ± SD 99.82 ± 1.458
Benzocaine 4 4.01 100.25
101.61 ± 1.248 8 8.14 101.75
12 11.84 98.67
Mean ± SD 99.98 ± 0.804
Method C is ratio difference, method D is ratio derivative spectra spectrophotometric method.
* Average of three experiments.
a Batch No. 857103.1
Spectrophotometric methods for determination of antipyrine and benzocaine 1874.2. Analysis of Otosept ear drops by the proposed methods
The proposed methods were also used for the determination of
An and BE in its pharmaceutical formulation. Satisfying
results were obtained and listed in Tables 2 and 3.5. Conclusion
The proposed dual wavelength method was found to be
simpler for quantitative determination of benzocaine and
antipyrine HCl in laboratory prepared mixture in addition topharmaceutical formulation. The main disadvantage of this
method is the restriction in the choice of the selected wave-
lengths which are restricted to those wavelengths with constant
absorbance of the interfering substance. This lead to the neces-
sity of critical measurement of the absorbance of the compo-
nent of interest, as any minor change in the selected
wavelength will affect the results and subsequently shows poor
reproducibility. Another disadvantage is the poor values
obtained from absorbance differences of the two components
which lead to poor sensitivity (as in benzocaine
4–20 lg mL1). The proposed ﬁrst derivative method (coupled
with isoabsorpative point), ratio difference and derivative ratio
Table 4 Statistical comparison of the results obtained by the proposed spectrophotometric methods and the reported methods for the
determination of antipyrine and benzocaine in pure powder form.
Items Antipyrine Benzocaine
Method A Method B Method C Method D Reported
method a
Method A Method B Method C Method D Reported
method a
Mean 100.05 99.96 100.09 100.04 100.22 100.12 99.39 99.37 99.61 99.47
SD 0.763 0.679 0.662 0.789 1.375 0.973 1.419 1.660 1.127 1.071
n 6 6 6 6 6 7 7 7 7 7
Variance 0.582 0.461 0.438 0.623 1.891 0.947 2.014 2.756 1.270 1.147
Student’s t test 0.265 0.415 0.209 0.278 1.188 0.119 0.134 0.238
(2.228)* (2.228)* (2.228)* (2.228)* (2.149)* (2.149)** (2.149)* (2.149)*
F test 3.25 4.10 4.32 3.04 1.21 1.76 2.40 1.11
(5. 05)* (5. 05)* (5. 05)* (5.05)* (4.28)* (4.28)* (4.28)* (4.28)*
Method A is dual wavelength, method B is ﬁrst derivative coupled with isoabsorpative point, method C is ratio difference, method D is ratio
derivative spectra spectrophotometric method.
* Figure between parenthesis are the corresponding tabulated values (p= 0.05).
a Ref. [30] HPLC method using C8(5 lm, 4.6  150 mm ID), mobile phase consisted of acetonitrile–phosphate buffer of pH 5.5 (25:75, v/v)
and UV detection at 270 nm.
Table 5 Analysis of antipyrine and benzocaine in laboratory prepared mixtures by the proposed spectrophotometric methods.
Mixture composition
(lg mL1)
Method A Method B Method C Method D
Antipyrine Benzocaine Antipyrine* Benzocaine* Antipyrine* Benzocaine* Antipyrine* Benzocaine* Antipyrine* Benzocaine*
30 10 100.01 99.85 99.73 101.51 100.52 100.63 100.67 100.79
20 10 98.65 100.59 98.95 101.26 99.08 99.20 99.45 100.39
10 10 98.15 100.84 98.63 100.77 97.98 99.61 98.81 99.79
5 10 98.61 101.32 100.46 101.26 98.14 100.52 99.29 100.35
40 10 98.48 98.13 97.56 103.24 98.94 97.81 99.47 98.91
Mean ± SD 98.78
± 0.717
100.15
± 1.246
99.07
± 1.102
101.61
± 0.952
98.93
± 1.011
99.55
± 1.147
99.55
± 0.750
100.07
± 1.132
Method A is dual wavelength, Method B is ﬁrst derivative coupled with isoabsorpative point, Method C is ratio difference, Method D is ratio
derivative spectra spectrophotometric method.
* Average of three determinations.
188 H.A. Mereyspectra method, provide simple and rapid determination of
cited drugs without prior separation with minimum calculation
steps and higher sensitivity (as in benzocaine 1–20 lg mL1).
The proposed methods were found to be sensitive and selective
and do not require complex algorithm, software programs (like
matlab) or sophisticated calculation, thus, could be easily
applied in QC laboratories lacking liquid chromatographic
instruments.Conflict of interest
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